From: Acromegaly and thyroid cancer: analysis of evolution in a series of patients
Potential risks factors for unfavorable DTC evolution | Age at diagnosis of DTC (years) Median (range) | IGF-1 at diagnosis of DTC (ULN) Median (range) | Time between DTC diagnosis and acromegaly control (years) Median (range) | Insulin resistance n (%) |
---|---|---|---|---|
Stage (n = 24) | ||||
1 (n = 19) | – | 1.19 (0.32–4.8) | 0.83 (0–7) | 8 (42.1) |
2 (n = 4) | 1.52 (1.32–1.70) | 2.25 (1–3.6) | 1 (25) | |
4b (n = 1) | 2.31 | 0 | 0 | |
p-value | – | 0.55 | 0.36 | 1 |
Initial recurrence risk (n = 24) | ||||
Low (n = 21) | 51.5 (18–68) | 1.44 (0.32–4.8) | 1.25 (0–7) | 8 (40) |
Intermediate (n = 2) | 55.5 (42–69) | 0.97 (0.64–1.31) | 2.13 (0.66–3.6) | 0 |
High (n = 1) | 66 | 2.31 | 0 | 0 |
p-value | 0.33 | 0.33 | 0.69 | 0.68 |
Initial response (n = 23) | ||||
Excellent (n = 12) | 58.5 (18–69) | 1.4 (0.32–3.09) | 0.5 (0–7) | 6 (50) |
Indeterminate (n = 7) | 50 (37–68) | 1.34 (0.64–4.4) | 0.83 (0–2.3) | 3 (42.9) |
Biochemical incomplete (n = 3) | 37 (37–38) | 3.37 (1.94–4.8) | 3 (0.25–4) | 0 |
Structural Incomplete (n = 1) | 66 | 2.31 | 0 | 0 |
p-value | 0.40 | 0.65 | 0.79 | 0.42 |
Response at the end of follow-up (n = 23) | ||||
No evidence of disease (n = 19) | 50 (18–69) | 1.21 (0.32–4.4) | 1 (0–7) | 7 (36.8) |
Indeterminate (n = 2) | 65 (62–68) | 1.8 (0.98–2.6) | 1.8 (0–3.6) | 1 (50) |
Biochemical incomplete (n = 1) | 37 | 1.7 | 0 | 0 |
Structural Incomplete (n = 1) | 66 | 2.31 | 0 | 0 |
p-value | 0.23 | 0.30 | 0.87 | 0.71 |